Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' TRICOT G' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 169 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Fassas, ABT; Buddharaju, LN; Rapoport, A; Cottler-Fox, M; Drachenberg, C; Meisenberg, B; Tricot, G
      Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation

      LEUKEMIA & LYMPHOMA
    2. Fassas, A; Gojo, I; Rapoport, A; Cottler-Fox, M; Meisenberg, B; Papadimitriou, JC; Tricot, G
      Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy

      BONE MARROW TRANSPLANTATION
    3. Barlogie, B; Tricot, G; Anaissie, E
      Thalidomide in the management of multiple myeloma

      SEMINARS IN ONCOLOGY
    4. Fassas, A; Tricot, G
      Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

      SEMINARS IN HEMATOLOGY
    5. Barlogie, B; Zangari, M; Spencer, T; Fassas, A; Anaissie, E; Badros, A; Cromer, J; Tricot, G
      Thalidomide in the management of multiple myeloma

      SEMINARS IN HEMATOLOGY
    6. Badros, A; Barlogie, B; Siegel, E; Roberts, J; Langmaid, C; Zangari, M; Desikan, R; Shaver, MJ; Fassas, A; McConnell, S; Muwalla, F; Barri, Y; Anaissie, E; Munshi, N; Tricot, G
      Results of autologous stem cell transplant in multiple myeloma patients with renal failure

      BRITISH JOURNAL OF HAEMATOLOGY
    7. Badros, A; Barlogie, B; Siegel, E; Morris, C; Desikan, R; Zangari, M; Fassas, A; Anaissie, E; Munshi, N; Tricot, G
      Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

      BRITISH JOURNAL OF HAEMATOLOGY
    8. Sawyer, JR; Lukacs, JL; Thomas, EL; Swanson, CM; Goosen, LS; Sammartino, G; Gilliland, JC; Munshi, NC; Tricot, G; Shaughnessy, JD; Barlogie, B
      Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma

      BRITISH JOURNAL OF HAEMATOLOGY
    9. Fassas, ABT; Bolanos-Meade, J; Buddharaju, LN; Rapoport, A; Cottler-Fox, M; Chen, T; Lovchik, JC; Cross, A; Tricot, G
      Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma

      BRITISH JOURNAL OF HAEMATOLOGY
    10. Desikan, KR; Tricot, G; Munshi, NC; Anaissie, E; Spoon, D; Fassas, A; Toor, A; Zangari, M; Badros, A; Morris, C; Vesole, DH; Siegel, D; Jagannath, S; Barlogie, B
      Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone

      BRITISH JOURNAL OF HAEMATOLOGY
    11. Zangari, M; Anaissie, E; Barlogie, B; Badros, A; Desikan, R; Gopal, AV; Morris, C; Toor, A; Siegel, E; Fink, L; Tricot, G
      Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy

      BLOOD
    12. Badros, A; Barlogie, B; Morris, C; Desikan, R; Martin, SR; Munshi, N; Zangari, M; Mehta, J; Toor, A; CottlerFox, M; Fassas, A; Aniassie, E; Schichman, S; Tricot, G
      High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001)

      BLOOD
    13. Barlogie, B; Desikan, R; Eddlemon, P; Spencer, T; Zeldis, J; Munshi, N; Badros, A; Zangari, M; Anaissie, E; Epstein, J; Shaughnessy, J; Ayers, D; Spoon, D; Tricot, G
      Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 studyof 169 patients

      BLOOD
    14. Badros, A; Barlogie, B; Morris, C; Desikan, R; Martin, SR; Munshi, N; Zangari, M; Toor, A; Cottler-Fox, M; Fassas, A; Aniassie, E; Schichman, S; Tricot, G
      High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

      BLOOD
    15. Desikan, KR; Tricot, G; Dhodapkar, M; Fassas, A; Siegel, D; Vesole, DH; Jagannath, S; Singhal, S; Mehta, J; Spoon, D; Anaissie, E; Barlogie, B; Munshi, N
      Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone

      BONE MARROW TRANSPLANTATION
    16. Tricot, G
      New insights into role of microenvironment in multiple myeloma

      LANCET
    17. Fassas, ABT; Rapoport, AP; Cottler-Fox, M; Chen, T; Tricot, G
      Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation

      BRITISH JOURNAL OF HAEMATOLOGY
    18. Shaughnessy, J; Tian, E; Sawyer, J; Bumm, K; Landes, R; Badros, A; Morris, C; Tricot, G; Epstein, J; Barlogie, B
      High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH

      BLOOD
    19. Desikan, R; Barlogie, D; Sawyer, J; Ayers, D; Tricot, G; Badros, A; Zangari, M; Munshi, NC; Anaissle, E; Spoon, D; Siegel, D; Jagannath, S; Vesole, D; Epstein, J; Shaughnessy, J; Fassas, A; Lim, S; Roberson, P; Crowley, J
      Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

      BLOOD
    20. Lacerna, L; Sheridan, WP; Basser, R; Begley, CG; Crawford, J; Demetri, G; Moskowitz, CH; Tricot, G; Weaver, A; Glaspy, JA
      Stem cell factor

      HEMATOPOIETIC STEM CELL TRANSPLANTION
    21. Siegel, DS; Lim, SH; Tricot, G; Desikan, KR; Fassas, A; Mehta, J; Singhal, S; Anaissie, E; Jagannath, S; Barlogie, B
      Stem cell transplantation for multiple myeloma - 10 years later

      HEMATOPOIETIC STEM CELL TRANSPLANTION
    22. Fassas, A; Jagannath, S; Desikan, KR; Shah, HR; Shaver, R; Waldron, J; Munshi, NC; Barlogie, B; Tricot, G
      Lymphomatoid granulomatosis following autologous stem cell transplantation

      BONE MARROW TRANSPLANTATION
    23. Berlyn, KA; Ponniah, S; Stass, SA; Malone, JG; Hamlin-Green, G; Lim, JK; Cottler-Fox, M; Tricot, G; Alexander, RB; Mann, DL; Malone, RW
      Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy

      JOURNAL OF BIOTECHNOLOGY
    24. Fassas, ABT; Desikan, KR; Siegel, D; Golper, TA; Munshi, NC; Barlogie, B; Tricot, G
      Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma

      BRITISH JOURNAL OF HAEMATOLOGY
    25. Desikan, R; Dhodapkar, M; Siegel, D; Fassas, A; Singh, J; Singhal, S; Mehta, J; Vesole, D; Tricot, G; Jagannath, S; Anaissie, E; Barlogie, B; Munshi, NC
      High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    26. Siegel, DS; Desikan, KR; Mehta, J; Singhal, S; Fassas, A; Munshi, N; Anaissie, E; Naucke, S; Ayers, D; Spoon, D; Vesole, D; Tricot, G; Barlogie, B
      Age is not a prognostic variable with autotransplants for multiple myeloma

      BLOOD
    27. Barlogie, B; Jagannath, S; Desikan, KR; Mattox, S; Vesole, D; Siegel, D; Tricot, G; Munshi, N; Fassas, A; Singhal, S; Mehta, J; Anaissie, E; Dhodapkar, D; Naucke, S; Cromer, J; Sawyer, J; Epstein, J; Spoon, D; Ayers, D; Cheson, B; Crowley, J
      Total therapy with tandem transplants for newly diagnosed multiple myeloma

      BLOOD
    28. DESIKAN KR; JAGANNATH S; SIEGEL D; NELSON J; BRACY D; BARLOGIE B; TRICOT G
      COLLECTION OF MORE HEMATOPOIETIC PROGENITOR CELLS WITH LARGE-VOLUME LEUKAPHERESIS IN PATIENTS WITH MULTIPLE-MYELOMA

      Leukemia & lymphoma
    29. Dhodapkar, MV; Weinstein, R; Tricot, G; Jagannath, S; Parfitt, AM; Manolagas, SC; Barlogie, B
      Biologic and therapeutic determinants of bone mineral density in multiple myeloma

      LEUKEMIA & LYMPHOMA
    30. DESIKAN KR; BARLOGIE B; JAGANNATH S; VESOLE DH; SIEGEL D; FASSAS A; MUNSHI N; SINGHAL S; MEHTA J; TINDLE S; NELSON J; BRACY D; MATTOX S; TRICOT G
      COMPARABLE ENGRAFTMENT KINETICS FOLLOWING PERIPHERAL-BLOOD STEM-CELL INFUSION MOBILIZED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR WITH OR WITHOUT CYCLOPHOSPHAMIDE IN MULTIPLE-MYELOMA

      Journal of clinical oncology
    31. BARLOGIE B; TRICOT G; DESIKAN KR; SIEGEL D; MEHTA J; SINGHAL S; JAGANNATH S
      DOUBLE AUTOTRANSPLANTS (DAT) FOR 542 PATIENTS WITH MULTIPLE-MYELOMA (MM)

      Bone marrow transplantation
    32. MEHTA J; TRICOT G; JAGANNATH S; AYERS D; SINGHAL S; SIEGEL D; DESIKAN K; MUNSHI N; FASSAS A; MATTOX S; VESOLE D; CROWLEY J; BARLOGIE B
      SALVAGE AUTOLOGOUS OR ALLOGENEIC TRANSPLANTATION FOR MULTIPLE-MYELOMAREFRACTORY TO OR RELAPSING AFTER A FIRST-LINE AUTOGRAFT

      Bone marrow transplantation
    33. BARLOGIE B; JAGANNATH S; NAUCKE S; MATTOX S; BRACY D; CROWLEY J; TRICOT G; ALEXANIAN R
      LONG-TERM FOLLOW-UP AFTER HIGH-DOSE THERAPY FOR HIGH-RISK MULTIPLE-MYELOMA

      Bone marrow transplantation
    34. BERNSTEIN SH; NADEMANEE AP; VOSE JM; TRICOT G; FAY JW; NEGRIN RS; DIPERSIO J; RONDON G; CHAMPLIN R; BARNETT MJ; CORNETTA K; HERZIG GP; VAUGHAN W; GEILS G; KEATING J; MESSNER H; WOLFF SN; MILLER KB; LINKER C; CAIRO M; HELLMANN S; ASHBY M; STRYKER S; NASH RA
      A MULTICENTER STUDY OF PLATELET RECOVERY AND UTILIZATION IN PATIENTS AFTER MYELOABLATIVE THERAPY AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION

      Blood
    35. ZENT CS; WILSON CS; TRICOT G; JAGANNATH S; SIEGEL D; DESIKAN KR; MUNSHI N; BRACY D; BARLOGIE B; BUTCH AW
      OLIGOCLONAL PROTEIN BANDS AND IG ISOTYPE SWITCHING IN MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE THERAPY AND HEMATOPOIETIC-CELL TRANSPLANTATION

      Blood
    36. SAWYER JR; TRICOT G; MATTOX S; JAGANNATH S; BARLOGIE B
      JUMPING TRANSLOCATIONS OF CHROMOSOME 1Q IN MULTIPLE-MYELOMA - EVIDENCE FOR A MECHANISM INVOLVING DECONDENSATION OF PERICENTROMERIC HETEROCHROMATIN

      Blood
    37. TRICOT G; GAZITT Y; LEEMHUIS T; JAGANNATH S; DESIKAN KR; SIEGEL D; FASSAS A; TINDLE S; NELSON J; JUTTNER C; TSUKAMOTO A; HALLAGAN J; ATKINSON K; READING C; HOFFMAN R; BARLOGIE B
      COLLECTION, TUMOR CONTAMINATION, AND ENGRAFTMENT KINETICS OF HIGHLY PURIFIED HEMATOPOIETIC PROGENITOR CELLS TO SUPPORT HIGH-DOSE THERAPY INMULTIPLE-MYELOMA

      Blood
    38. DESIKAN KR; DHODAPKAR MV; HOUGH A; WALDRON T; JAGANNATH S; SIEGEL D; BARLOGIE B; TRICOT G
      INCIDENCE AND IMPACT OF LIGHT-CHAIN ASSOCIATED (AL) AMYLOIDOSIS ON THE PROGNOSIS OF PATIENTS WITH MULTIPLE-MYELOMA TREATED WITH AUTOLOGOUS TRANSPLANTATION

      Leukemia & lymphoma
    39. DHODAPKAR MV; JAGANNATH S; VESOLE D; MUNSHI N; NAUCKE S; TRICOT G; BARLOGIE B
      TREATMENT OF AL-AMYLOIDOSIS WITH DEXAMETHASONE PLUS ALPHA-INTERFERON

      Leukemia & lymphoma
    40. JAGANNATH S; TRICOT G; BARLOGIE B
      AUTOTRANSPLANTS IN MULTIPLE-MYELOMA - PUSHING THE ENVELOPE

      Hematology/oncology clinics of North America
    41. FEINMAN R; SAWYER J; HARDIN J; TRICOT G
      CYTOGENETICS AND MOLECULAR-GENETICS IN MULTIPLE-MYELOMA

      Hematology/oncology clinics of North America
    42. TRICOT G; SAWYER JR; JAGANNATH S; DESIKAN KR; SIEGEL D; NAUCKE S; MATTOX S; BRACY D; MUNSHI N; BARLOGIE B
      UNIQUE ROLE OF CYTOGENETICS IN THE PROGNOSIS OF PATIENTS WITH MYELOMARECEIVING HIGH-DOSE THERAPY AND AUTOTRANSPLANTS

      Journal of clinical oncology
    43. JAGANNATH S; VESOLE DH; ZHANG M; DESIKAN KR; COPELAND N; JAGANNATH M; BRACY D; JONES R; CROWLEY J; TRICOT G; BARLOGIE B
      FEASIBILITY AND COST-EFFECTIVENESS OF OUTPATIENT AUTOTRANSPLANTS IN MULTIPLE-MYELOMA

      Bone marrow transplantation
    44. MEHTA J; TRICOT G; JAGANNATH S; DESIKAN KR; SIEGEL D; SINGHAL S; MUNSHI N; VESOLE D; MATTOX S; BRACY D; BARLOGIE B
      HIGH-DOSE CHEMOTHERAPY WITH CARBOPLATIN, CYCLOPHOSPHAMIDE AND ETOPOSIDE AND AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE-MYELOMA RELAPSING AFTERA PREVIOUS TRANSPLANT

      Bone marrow transplantation
    45. GUBA SC; VESOLE DH; JAGANNATH S; BRACY D; BARLOGIE B; TRICOT G
      PERIPHERAL STEM-CELL MOBILIZATION AND ENGRAFTMENT IN PATIENTS OVER AGE 60

      Bone marrow transplantation
    46. BARLOGIE B; JAGANNATH S; EPSTEIN J; MUNSHI N; SIEGEL D; DESIKAN KR; FEINMAN R; HSU PL; VONBREMEN K; TRICOT G
      BIOLOGY AND THERAPY OF MULTIPLE-MYELOMA IN 1996

      Seminars in hematology
    47. DESIKAN KR; NELSON J; TINDLE S; SIEGEL D; SINGHAL S; FASSAS A; TRICOT G; JAGANNATH S; BARLOGIE B; MEHTA J
      STEM-CELL COLLECTION IN MYELOMA PATIENTS - REPEATED ATTEMPTS MAY BE NEEDED TO OBTAIN AN ADEQUATE HARVEST IN PATIENTS FAILING TO COLLECT WELL INITIALLY

      Blood
    48. MEHTA J; SINGHAL S; FASSAS A; HILTON J; SIEGEL D; DESIKAN K; JAGANNATH S; ANAISSIE E; BARLOGIE B; TRICOT G
      AUTOLOGOUS MARROW INFUSION WITHOUT FURTHER CONDITIONING FOR LIFE-THREATENING GVHD - RESOLUTION OF GVHD WITH PERSISTENT DONOR-TYPE CHIMERISM

      Blood
    49. SAWYER JR; TRICOT G; MATTOX S; JAGANNATH S; BARLOGIE B
      JUMPING TRANSLOCATIONS OF CHROMOSOME 1Q IN MULTIPLE-MYELOMA - EVIDENCE FOR A MECHANISM INVOLVING DECONDENSATION OF PERICENTROMERIC HETEROCHROMATIN

      Blood
    50. WALDRON J; JAZIEH R; JAGANNATH S; DESIKAN KR; SIEGEL D; FASSAS A; SINGHAL S; MEHTA J; TRICOT G; VESOLE D; WILSON C; HOUGH A; NAUCKE S; SPOON D; BARLOGIE B
      BONE-MARROW MORPHOLOGY (BMM) ADDS CRITICAL PROGNOSTIC INFORMATION TO OTHER STANDARD PARAMETERS (SP) INCLUDING CYTOGENETICS AMONG NEWLY-DIAGNOSED MULTIPLE-MYELOMA (MM) PATIENTS (PTS) RECEIVING TOTAL THERAPY (TT)

      Blood
    51. MUNSHI NC; TRICOT G; JAGANNATH S; MEHTA J; DESIKAN K; SIEGLE S; SINGHAL S; FASSAS A; FINK L; SCHICHMAN S; CHIANG Y; REYNOLDS C; BARLOGIE B
      CLINICAL-RESULTS OF THYMIDINE KINASE (TK) GENE TRANSDUCED DONOR LYMPHOCYTE INFUSION FOLLOWING ALLOGENEIC TRANSPLANTATION IN MYELOMA

      Blood
    52. SIEGEL D; MEHTA J; ANAISSIE E; DESIKAN KR; FASSAS A; JAGANNATH S; SINGHAL S; TRICOT G; MUNSHI N; BARNHART S; HOOD S; SPOON D; MATTOX S; BARLOGIE B
      PROLONGED IMMUNOSUPPRESSION AFTER CD34(+) OR CD34(+) THY-1(+)/LIN(ASTERISK) SELECTED AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTS (TX) FOR MULTIPLE-MYELOMA/

      Blood
    53. KONERU B; ANAISSIE E; TRICOT G; JAGANNATH S; MEHTA J; DESIKAN R; SIEGEL D; SINGHAL S; FASSAS A; BARLOGIE B
      HIGH-INCIDENCE OF AND MORTALITY FROM TOXOPLASMA-GONDII INFECTIONS IN T-CELL DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS

      Blood
    54. MEHTA J; AYERS D; MATTOX S; SINGHAL S; SIEGEL D; FASSAS A; HILTON J; ANAISSIE E; DESIKAN K; MUNSHI N; JAGANNATH S; TRICOT G; BARLOGIE B
      ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA - SINGLE-CENTER EXPERIENCE OF 97 PATIENTS

      Blood
    55. DESIKAN KR; FASSAS A; SIEGEL D; JAGANNATH S; MEHTA J; SINGHAL S; BRACY D; TRICOT G; BARLOGIE B
      SUPERIOR OUTCOME WITH MELPHALAN-200 MG M(3) (MEL200) FOR SCHEDULED 2ND-AUTOTRANSPLANT COMPARED MEL+TBI OR CTX FOR MYELOMA (MM) IN PRE-TX-2 PR/

      Blood
    56. DESIKAN KR; MEHTA J; FASSAS A; SIEGEL D; MUNSHI N; SINGHAL S; JAGANNATH S; TRICOT G; BARLOGIE B
      PERIPHERAL-BLOOD STEM-CELL (PBSC) COLLECTION WITH G-CSF ALONE IN MULTIPLE-MYELOMA (MM) - FACTORS ASSOCIATED WITH POST TRANSPLANT (TX) RECOVERY

      Blood
    57. KONERU B; HOUGH A; FASSAS A; TRICOT G; DESIKAN KR; SIEGEL D; JAGANNATH S; SINGHAL S; MEHTA J; BARLOGIE B; ANAISSIE E
      AUTOPSY REVIEW IN MULTIPLE-MYELOMA (MM) REVEALS ASPERGILLOSIS (ASP) AS A SIGNIFICANT CAUSE OF DEATH AFTER HIGH-DOSE THERAPY (HDT) ESPECIALLY WITH ALLOTRANSPLANTS (ALLO-TX)

      Blood
    58. MUNSHI NC; JAGANNATH S; DESIKAN K; MEHTA J; SINGHAL S; SIEGLE S; FASSAS A; AYERS D; MATTOX S; ANAISSIE A; TRICOT G; BARLOGIE B
      SIGNIFICANCE OF RECOVERY OF UNINVOLVED IMMUNOGLOBULINS (UIG) FOLLOWING TOTAL THERAPY (TT) WITH TANDEM AUTOTRANSPLANTS IN NEWLY-DIAGNOSED MULTIPLE-MYELOMA (MM)

      Blood
    59. GOVINDARAJAN R; TRICOT G; JAGANNATH S; FLICK JT; SAWYER J; AYERS D; BARLOGIE B
      SECONDARY NEOPLASMS (SN) FOLLOWING AUTO-TRANSPLANTS (AT) FOR MULTIPLE-MYELOMA (MM)

      Blood
    60. JAGANNATH S; VESOLE D; SIEGEL D; DESIKAN KR; MUNSHI N; FASSAS A; SINGHAL S; MEHTA J; SPOON D; TRICOT G; EVANS T; NAUCKE S; TINDLE S; NELSON J; COPELAND N; BARLOGIE B
      FINAL ANALYSIS OF TOTAL THERAPY (TT) WITH TANDEM TRANSPLANTS (TX) FOR231 NEWLY-DIAGNOSED PATIENTS (PTS) WITH MULTIPLE-MYELOMA (MM)

      Blood
    61. SIEGEL D; JAGANNATH S; DESIKAN KR; TRICOT G; VESOLE D; FASSAS A; SINGHAL S; MEHTA J; HOOD S; BARLOGIE B
      SIMILAR PROGNOSIS AFTER TANDEM AUTOTRANSPLANTS (TAT) FOR MYELOMA LESS-THAN-65 YR AND GREATER-THAN-OR-EQUAL-TO-65 YR

      Blood
    62. MEHTA J; AYERS D; MATTOX S; SINGH J; SINGHAL S; SIEGEL D; FASSAS A; DESIKAN K; VESOLE D; MUNSHI N; ANAISSIE E; TRICOT G; BARLOGIE B; JAGANNATH S
      HIGH-DOSE MELPHALAN AND AUTOTRANSPLANTATION IN MYELOMA WITH RENAL IMPAIRMENT - A MATCHED-PAIR COMPARISON WITH PATIENTS WITHOUT RENAL-FAILURE

      Blood
    63. FASSAS A; DESIKAN KR; GOLPER T; SIEGEL D; SINGHAL S; MEHTA J; MATTOX S; JAGANNATH S; TRICOT G; BARLOGIE B
      TUMOR LYSIS SYNDROME (TLS) FOLLOWING INTERMEDIATE AND HIGH-DOSE THERAPY IN PATIENTS (PTS) WITH MULTIPLE-MYELOMA (MM) - ASSOCIATION WITH HIGH TUMOR MASS, IMMATURE MORPHOLOGY, HIGH LABELING INDEX (LI) AND ABNORMAL CYTOGENETICS (CG)

      Blood
    64. SINGHAL S; MEHTA J; HOOD S; MATTOX S; SIEGEL D; FASSAS A; DESIKAN K; ANAISSIE E; TRICOT G; JAGANNATH S; BARLOGIE B
      3RD TRANSPLANTS FOR MYELOMA RELAPSING AFTER 2 PRIOR AUTOGRAFTS

      Blood
    65. SINGHAL S; HOOD S; MEHTA J; SIEGEL D; FASSAS A; DESIKAN K; NELSON J; TINDLE S; JAGANNATH S; TRICOT G; BARLOGIE B
      COLLECTION OF PERIPHERAL-BLOOD STEM-CELLS AFTER A PRECEDING AUTOTRANSPLANT

      Blood
    66. MUNSHI NC; GOVINDARAJAN R; DRAKE R; DING LM; IYER R; SAYLORS R; KORNBLUTH J; MARCUS S; CHIANG Y; ENNIST D; KWAK L; REYNOLDS C; TRICOT G; BARLOGIE B
      THYMIDINE KINASE (TK) GENE-TRANSDUCED HUMAN-LYMPHOCYTES CAN BE HIGHLYPURIFIED, REMAIN FULLY FUNCTIONAL, AND ARE KILLED EFFICIENTLY WITH GANCICLOVIR

      Blood
    67. BARLOGIE B; JAGANNATH S; VESOLE DH; NAUCKE S; CHESON B; MATTOX S; BRACY D; SALMON S; JACOBSON J; CROWLEY J; TRICOT G
      SUPERIORITY OF TANDEM AUTOLOGOUS TRANSPLANTATION OVER STANDARD THERAPY FOR PREVIOUSLY UNTREATED MULTIPLE-MYELOMA

      Blood
    68. TRICOT G; ALBERTS DS; JOHNSON C; ROE DJ; DORR RT; BRACY D; VESOLE DH; JAGANNATH S; MEYERS R; BARLOGIE B
      SAFETY OF AUTOTRANSPLANTS WITH HIGH-DOSE MELPHALAN IN RENAL-FAILURE -A PHARMACOKINETIC AND TOXICITY STUDY

      Clinical cancer research
    69. CORNETTA K; SROUR EF; MOORE A; DAVIDSON A; BROUN ER; HROMAS R; MOEN RC; MORGAN RA; RUBIN L; ANDERSON WF; HOFFMAN R; TRICOT G
      RETROVIRAL GENE-TRANSFER IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADULT ACUTE-LEUKEMIA

      Human gene therapy
    70. TRICOT G; JAGANNATH S; VESOLE DH; BRACY D; DESIKAN KR; SIEGEL D; BARLOGIE B
      HEMATOPOIETIC STEM-CELL TRANSPLANTS FOR MULTIPLE-MYELOMA

      Leukemia & lymphoma
    71. VESOLE DH; JAGANNATH S; TRICOT G; DESIKAN KR; SIEGEL D; BARLOGIE B
      AUTOLOGOUS BONE-MARROW AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATIONIN MULTIPLE-MYELOMA

      Cancer investigation
    72. RIGDEN JP; CORNETTA K; SROUR EF; HANNA M; BROUN ER; HROMAS R; BAUTE J; HILTON J; COX E; RUBIN L; GONIN R; TRICOT G
      MINIMIZING GRAFT-REJECTION IN ALLOGENEIC T-CELL-DEPLETED BONE-MARROW TRANSPLANTATION

      Bone marrow transplantation
    73. WEBER G; PRAJDA N; ABONYI M; LOOK KY; TRICOT G
      TIAZOFURIN - MOLECULAR AND CLINICAL ACTION

      Anticancer research
    74. TRICOT G; WEBER G
      BIOCHEMICALLY TARGETED THERAPY OF REFRACTORY LEUKEMIA AND MYELOID BLAST CRISIS OF CHRONIC GRANULOCYTIC-LEUKEMIA WITH TIAZOFURIN, A SELECTIVE BLOCKER OF INOSINE 5'-PHOSPHATE DEHYDROGENASE-ACTIVITY

      Anticancer research
    75. GOVINDARAJAN R; JAGANNATH S; FLICK JT; VESOLE DH; SAWYER J; BARLOGIE B; TRICOT G
      PRECEDING STANDARD THERAPY IS THE LIKELY CAUSE OF MDS AFTER AUTOTRANSPLANTS FOR MULTIPLE-MYELOMA

      British Journal of Haematology
    76. VESOLE DH; TRICOT G; JAGANNATH S; DESIKAN KR; SIEGEL D; BRACY D; MILLER L; CHESON B; CROWLEY J; BARLOGIE B
      AUTOTRANSPLANTS IN MULTIPLE-MYELOMA - WHAT HAVE WE LEARNED

      Blood
    77. SINGHAL S; SIEGEL D; MATTOX S; JAGANNATH S; TRICOT G; MEHTA J; DESIKAN KR; MUNSHI N; ZENT C; BARLOGIE B
      CENTRAL-NERVOUS-SYSTEM INVOLVEMENT IN MULTIPLE-MYELOMA

      Blood
    78. JAZIEH AR; BRACY D; SPINKS C; SIEGEL D; DESIKAN KR; JAGANNATH S; HILLER FC; BARLOGIE B; TRICOT G
      CHANGES IN PULMONARY-FUNCTION TEST (PFT) FOLLOWING HIGH-DOSE CYCLOPHOSPHAMIDE AND MELPHALAN IN MULTIPLE-MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AT)

      Blood
    79. HSU PL; MANJGALADZE M; TIAN E; BARLOGIE B; TRICOT G
      GROWTH-INHIBITION AND APOPTOSIS OF MYELOMA CELL-LINES, EXPRESSING HIGH-LEVELS OF BCL-2, BY PHENYLACETATE (PA) AND PHENYLBUTYRATE (PB) IS ENHANCED BY TAXOL THROUGH INDUCTION OF PHOSPHORYLATION OF BCL-2

      Blood
    80. SIEGEL DS; JAGANNATH S; DESIKAN KR; TRICOT G; BRACY D; MADDOX S; BARLOGIE B; VESOLE DH
      FEASIBILITY OF HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL-BLOOD STEM-CELLSUPPORT FOR MULTIPLE-MYELOMA PATIENTS OVER THE AGE OF 70

      Blood
    81. JAGANNATH S; TRICOT G; DESIKAN KR; NAUCKE S; MATTOX S; DICKE K; BARLOGIE B
      20-PERCENT 9 YEAR SURVIVAL AFTER HIGH-DOSE THERAPY (HDT)+ -ABMT FOR HIGH-RISK MYELOMA (MM)LESS-THAN-OR-EQUAL-TO-AGE-50 OR B2M-LESS-THAN-OR-EQUAL-TO-2.5 MG/L PRE-HDT/

      Blood
    82. TRICOT G; JAGANNATH S; DESIKAN KR; MUNSHI N; SIEGEL D; BRACY D; BARLOGIE B
      SALVAGE TRANSPLANT FOR EARLY RELAPSE (LESS-THAN-OR-EQUAL-TO-1 YEAR) AFTER A SINGLE AUTOTRANSPLANT (AT) ARE EFFECTIVE AND IMPROVE OUTCOME

      Blood
    83. ROONEY D; CRIPE L; KNEEBONE P; TRICOT G; RUTLEDGE C; GORDON M
      MODIFICATION OF INDUCTION THERAPY FOR ACUTE MYELOID-LEUKEMIA (AML) WITH THE ADDITION OF HIGH-DOSE ARA-C (HDAC) ON DAYS 8-10

      Blood
    84. MUNSHI NC; JAGANNATH S; VESOLE D; DESIKAN KR; BARLOGIE B; TRICOT G
      GRAFT VS MYELOMA EFFECT - THYMIDINE KINASE (TK) GENE TRANSDUCED LYMPHOCYTE INFUSION FOLLOWING ALLOGENEIC TRANSPLANTATION IN MYELOMA

      Blood
    85. TRICOT G; BARLOGIE B; JAGANNATH S; DESIKAN KR; SIEGEL D; BRACY D; MATTOX S; NAUCKE S; MUNSHI N; SAWYER J
      BOTH TRANSLOCATIONS AND 11 13 ABNORMALITIES HAVE A DOMINANT PROGNOSTIC IMPLICATION AND PREDICT POOR OUTCOME IN PATIENTS (PTS) WITH MULTIPLE-MYELOMA (MM) TREATED WITH HIGH-DOSE THERAPY AND AUTOTRANSPLANTS (AT)/

      Blood
    86. TRICOT G; JAGANNATH S; DESIKAN KR; SIEGEL D; MUNSHI N; OLSON E; WYRES M; PARKER W; BARLOGIE B
      SUPERIOR MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) WITH R-METHUSCF (SCF) AND R-METHUG-CSF (FILGRASTIM) IN HEAVILY PRETREATEDMULTIPLE-MYELOMA (MM) PATIENTS

      Blood
    87. ZENT CS; TRICOT G; JAGANNATH S; SIEGEL D; DESIKAN KR; MUNSHI N; BRACY D; BARLOGIE B; BUTCH AW
      SERUM OLIGOCLONAL PROTEIN BANDS AND IMMUNNOGLOBULIN ISOTYPE SWITCH INPATIENTS (PTS) RECEIVING AUTOTRANSPLANTS (AT) FOR MULTIPLE-MYELOMA (MM)

      Blood
    88. JAZIEH AR; ANTGUACO E; BRACY D; MATTOX S; PETERSON L; JAGANNATH S; BARLOGIE B; DESIKAN KR; SIEGEL D; TRICOT G
      PERSISTENCE OF MAGNETIC-RESONANCE-IMAGING (MRI) ABNORMALITIES POSTTRANSPLANTATION DOES NOT PREDICT FOR EARLY RELAPSE IN MULTIPLE-MYELOMA (MM) PATIENTS WHO ACHIEVED COMPLETE REMISSION AFTER DOUBLE AUTOLOGOUS STEM-CELL TRANSPLANTS

      Blood
    89. MUNSHI NC; DESIKAN KR; JAGANNATH S; SIEGEL D; BRACY D; TRICOT G; BARLOGIE B
      DEXAMETHASONE, CYCLOPHOSPHAMIDE, ETOPOSIDE AND CISPLATINUM (DCEP), ANEFFECTIVE REGIMEN FOR RELAPSE AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS TRANSPLANTATION (AT)

      Blood
    90. SINGHAL S; TRICOT G; JAGANNATH S; MEHTA J; SIEGEL D; DESIKAN KR; MUNSHI N; VESOLE D; BRACY D; BARLOGIE B
      OUTCOME OF RELAPSE AFTER TRANSPLANTATION IN MYELOMA

      Blood
    91. SINGHAL S; BARLOGIE B; JAGANNATH S; BRACY D; MEHTA J; DESIKAN KR; SIEGEL D; MUNSHI N; TRICOT G
      FEASIBILITY AND EFFICACY OF 3RD TRANSPLANT PROCEDURES IN MYELOMA

      Blood
    92. MEHTA J; TRICOT G; JAGANNATH S; AYERS D; SINGHAL S; BRACY D; SIEGEL D; DESIKAN KR; MUNSHI N; VESOLE D; BARLOGIE B
      A SINGLE-CENTER, MATCHED-PAIR COMPARISON OF AUTOGRAFTING AND ALLOGRAFTING IN MULTIPLE-MYELOMA

      Blood
    93. DESIKAN KR; JAGANNATH S; SIEGEL D; MUNSHI N; BRACY D; BARLOGIE B; TRICOT G
      POSTTRANSPLANT ENGRAFTMENT KINETICS AND TOXICITIES IN MULTIPLE-MYELOMA (MM) PATIENTS (PTS) ARE COMPARABLE FOLLOWING MOBILIZATION OF PBSC WITH G-CSF WITH OR WITHOUT HIGH-DOSE CYCLOPHOSPHAMIDE (HD CTX)

      Blood
    94. JAGANNATH S; TRICOT G; VESOLE D; DESIKAN KR; MUNSHI N; SIEGEL D; CROWLEY J; BRACY D; MATTOX S; NAUCKE S; BARLOGIE B
      TOTAL THERAPY (TT) WITH TANDEM AUTOTRANSPLANTS (2-TX) FOR 231 NEWLY-DIAGNOSED PATIENTS (PTS) WITH MULTIPLE-MYELOMA (MM)

      Blood
    95. TRICOT G; VESOLE DH; JAGANNATH S; HILTON J; MUNSHI N; BARLOGIE B
      GRAFT-VERSUS-MYELOMA EFFECT - PROOF OF PRINCIPLE

      Blood
    96. GAZITT Y; TIAN EM; BARLOGIE B; READING CL; VESOLE DH; JAGANNATH S; SCHNELL J; HOFFMAN R; TRICOT G
      DIFFERENTIAL MOBILIZATION OF MYELOMA CELLS AND NORMAL HEMATOPOIETIC STEM-CELLS IN MULTIPLE-MYELOMA AFTER TREATMENT WITH CYCLOPHOSPHAMIDE AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

      Blood
    97. CHEN BP; FRASER C; READING C; MURRAY L; UCHIDA N; GALY A; SASAKI D; TRICOT G; JAGANNATH S; BARLOGIE B; TSUKAMOTO A; HOFFMAN R
      CYTOKINE-MOBILIZED PERIPHERAL-BLOOD CD34(-1(+)LIN(-) HUMAN HEMATOPOIETIC STEM-CELLS AS TARGET-CELLS FOR TRANSPLANTATION-BASED GENE-THERAPY()THY)

      Leukemia
    98. HOROWITZ; LEBKOWSKI J; SOUZA S; TRICOT G; OREILLY RJ; CHAMPLIN RE; OKARMA T
      SELECTIVE CD5 CD8 T-CELL SUBSET DEPLETION OF DONOR BONE-MARROW IN HLA-IDENTICAL SIBLING TRANSPLANTS COMPARED WITH A/

      Experimental hematology
    99. TRICOT G; VESOLE DH; JAGANNATH S; MUNSHI N; BARLOGIE B
      GRAFT-VERSUS-MYELOMA EFFECT - PROOF OF PRINCIPLE

      Experimental hematology
    100. GAZITT Y; TIAN E; BARLOGIE B; GROVE C; READING CC; VESOLE DH; JAGANNATH S; SCHNELL J; HOFFMAN R; TRICOT G
      DIFFERENTIAL MOBILIZATION OF MYELOMA CELLS AND NORMAL HEMATOPOIETIC STEM-CELLS IN MULTIPLE-MYELOMA PATIENTS FOLLOWING TREATMENT WITH CYCLOPHOSPHAMIDE AND GM-CSF

      Experimental hematology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/08/20 alle ore 13:20:16